Tom Heyman is an Executive Partner at Bioqube Ventures, following a 37-year career at Johnson & Johnson. Most recently, he served as President of Johnson & Johnson Innovation – JJDC, Inc., where he led the world’s oldest corporate life sciences venture fund, making strategic healthcare investments globally.

During his career, Tom held senior roles in business development, overseeing hundreds of transactions across early- and late-stage pharma, and served as CEO of Janssen Pharmaceutical NV in Belgium. He has played a pivotal role in building innovation ecosystems and scaling healthcare companies worldwide He currently serves on the boards of imec vzw (Belgium), Exelixis (Nasdaq: EXEL), Legend Biotech (Nasdaq: LEGN) and until recently Akero Therapeutics (Nasdaq: AKRO – to be acquired by Novo Nordisk).